Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer

Journal of Urology

Volumn 156, Issue 5, 1996, Pages 1691-1695

  Takeuchi, Shin Ichi ^a   Arai, Kyouko ^a   Saitoh, Hiroshi ^a   Yoshida, Ken Ichiro ^a   Miura, Masakazu ^a  

^a NONE

Author keywords

biological; neoplasm metastasis; prostatic neoplasms; tumor markers

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; PYRIDINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; URINALYSIS;

EID: 0029903420     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65484-3     Document Type: Article

References (23)

1. Pollen, J. J., Gerber, K., Ashburn, W. L. and Schmidt, J. D.: Nuclear bone imaging in metastatic cancer of the prostate. Cancer, 47: 2585, 1981.
2. Hortobagyi, G. N., Libshitz, H. I. and Seabold, J. E.: Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy. Cancer, 53: 577, 1984.
3. Blomqvist, C., Elomaa, I., Virkkunen, P., Porkka, L., Karonen, L. S.-L., Risteli, L. and Risteli, J.: The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. Cancer, 60: 2907, 1987.
4. Coleman, R. E., Whitaker, K. B., Moss, D. W., Mashiter, G., Fogelman, I. and Rubens, R. D.: Biochemical prediction of response of bone metastases to treatment. Brit. J. Cancer, 58: 205, 1988.
5. Campbell, F. C., Blarney, R. W., Woolfson, A. M., Elston, C. W. and Hosking, D. J.: Calcium excretion (Ca E) in metastatic breast cancer. Brit. J. Surg., 70: 202, 1983.
6. Stěpán, J. J., Mikulecký, M., Bek, V., Broulík, P. and Pacovský, V.: Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism. Neoplasma, 36: 495, 1989.
7. Miyamoto, K. K., McSherry, S. A., Robins, S. P., Besterman, J. M. and Mohler, J. L.: Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J. Urol., 151: 909, 1994.
8. Price, P. A., Partemore, J. G. and Deftos, L. J.: New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J. Clin. Invest., 66: 878, 1980.
9. Arai, Y., Takeuchi, H., Oishi, K. and Yoshida, O.: Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate, 20: 169, 1992.
10. Eyre, D. R. and Oguchi, H.: The hydroxypyridinium crosslinks of skeletal collagens: their measurement, properties and a proposed pathway of formation. Biochem. Biophys. Res. Commun., 92: 403, 1980.
11. Beardsworth, L. J., Eyre, D. R. and Dickson, I. R.: Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J. Bone Min. Res., 5: 671, 1990.
12. Segrest, J. P.: Urinary metabolites of collagen. Methods. Enzymol., 82: 398, 1982.
13. Uebelhart, D., Gineyts, E., Chapuy, M. C. and Delmas, P. D.: Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic disease. Bone Miner., 8: 87, 1990.
14. Uebelhart, D., Schlemmer, A., Johansen, J. S., Gineyts, E., Christiansen, C., and Delmas, P. D.: Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J. Clin. Endocr. Metab., 72: 367, 1991.
15. James, I. T., Perrett, D. and Thompson, P. W.: Rapid assay for hard tissue collagen cross-links using isocratic ion-pair reverse-phase liquid chromatography. J. Chromatogr., 525: 43, 1990.
16. Delmas, P. D., Schlemmer, A., Gineyts, E., Riis, B. and Christiansen, C.: Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J. Bone Mineral Res., 6: 639, 1991.
17. Robins, S. P., Black, D., Paterson, C. R., Reid, D. M., Duncan, A. and Seibel, M. J.: Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur. J. Clin. Invest., 21: 310, 1991.
18. Seibel, M. J., Duncan, A. and Robins, S. P.: Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J. Rheumatol., 16: 964, 1989.
19. Paterson, C. R., Robins, S. P., Horobin, J. M., Preece, P. E. and Cuschieri, A.: Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Brit. J. Cancer, 64: 884, 1991.
20. Body, J. J. and Delmas, P. D.: Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J. Clin. Endocr. Metab., 74: 471, 1992.
21. Coleman, R. E., Houston, S., James, I., Rodger, A., Rubens, R. D., Leonard, R. C. and Ford, J.: Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Brit. J. Cancer, 65: 766, 1992.
22. Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J. T., Todd, B., Soloway, S. and Moinuddin, M.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61: 195, 1988.
23. Lian, J. B. and Gundberg, C. M.: Osteocalcin. Biochemical considerations and clinical applications. Clin. Orthopaed. Related Res., 226: 267, 1988.